The Adapt Oculus trial is unique in that it includes a patient population often overlooked in clinical trials, patients ...

Xeris Biopharma benefits from the FDA's CRL to Corcept's relacorilant, removing a major competitive threat to Recorlev sales ...

The redesigned pens will reduce the amount of residual medication, effectively preventing users from extracting a fifth dose.

Cresilon announced its revolutionary hemostatic gel TRAUMAGEL(R) has received an Innovative Technology contract from Vizient(R) the nation's largest provider-driven healthcare performance improvement ...

Tyler Van Buren here, senior biotech analyst at TD Cowen. Thank you very much for joining TD Cowen's 46th Annual Healthcare Conference. For next session or first session of the day, actually, very ...

Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year period; Full-Year r ...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2025 Earnings Call Transcript February 26, 2026 Amphastar Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $0.73 EPS, ...

The redesigned pens will reduce the amount of residual medication, effectively preventing users from extracting a fifth dose.

AUSTIN, TX / ACCESS Newswire / March 2, 2026 / In modern metabolic medicine, few treatments have reshaped care like GLP-1 receptor agonists. If you are asking what is semaglutide, it is a prescription ...

Otsuka Pharmaceutical Canada Inc. (OCPI) and Lundbeck Canada Inc. (Lundbeck) have secured coverage of ABILIFY ASIMTUFII® for over 90 per cent of Canadians covered by public drug plans and almost 60 ...

A new analysis dives into why Europe’s eye clinics lag on biosimilars and how education, guidance, and smarter tenders could unlock €747 million in savings.